# HIV and HCC in Africa: The H2A Consortium

> **NIH NIH U54** · JOHNS HOPKINS UNIVERSITY · 2024 · $124,783

## Abstract

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as “NOT-CA-
24-028”
Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live
longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B
and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared
to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only
months. Proposed is an East and West African partnership between colleagues at Makerere University in
Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular
carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring
and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub-
Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments
to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by
developing local capacity and performing important research. Consortium activities are designed to enhance
both the clinical, population and translational research infrastructure and individual African investigator capacity
to conduct high-level, collaborative investigation of HIV, chronic infections and HCC. First, we will form a large,
prospective cohort of HBV and HBV/HIV co-infected persons to define who needs HBV treatment, determine
clinical responses, and characterize breakthrough HCC, while investigating novel biomarkers. To understand
our data demonstrating synergistic interaction between chronic HBV and Sm infections, we will examine HBV
clinical and immunological responses in the periphery and the liver in response to Sm treatment. HIV is
investigated as a key modifier of these relationships in both projects. Integrated within our scientific agenda,
early-stage African investigators will be provided mentoring and career development support while conducting
a collaborative pilot project leveraging Consortium resources. The impact of our integrated research and
capacity development activities will be establishment of the H2A Consortium as partnered Centers of
Excellence on HIV and HCC in East and West Africa.

## Key facts

- **NIH application ID:** 11089983
- **Project number:** 3U54CA254565-05S1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Gregory D Kirk
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $124,783
- **Award type:** 3
- **Project period:** 2020-09-09 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11089983

## Citation

> US National Institutes of Health, RePORTER application 11089983, HIV and HCC in Africa: The H2A Consortium (3U54CA254565-05S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11089983. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*